| Page 8 | Kisaco Research
 

Justin Byers

Founder and Chief Executive Officer
Axio BioPharma

Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.

Justin Byers

Founder and Chief Executive Officer
Axio BioPharma

Justin Byers

Founder and Chief Executive Officer
Axio BioPharma

Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.

Under Justin’s leadership, Axio has pioneered a data-rich, machine learning–powered approach that reduces process development timelines from years to days unlocking faster, more cost-efficient pathways for biotech partners. He has steered the company’s rapid growth, from establishing its state-of-the-art facilities to securing strategic partnerships, including collaborations to advance next-generation drug delivery technologies.

With a background at the intersection of biomanufacturing, technology, and entrepreneurship, Justin brings a vision of scaling biologics development with speed, reliability, and accessibility. He is committed to building Axio into a trusted partner for innovators worldwide, combining scientific rigor with cutting-edge AI to bring life-changing therapies to patients faster.

Author:

Dan O'Neil

Associate Professor in Companion Animal Epidemiology
Royal Veterinary College, University of London

Dan O'Neil

Associate Professor in Companion Animal Epidemiology
Royal Veterinary College, University of London

Author:

David Singleton

Director of Research
IVC Evidensia

David Singleton

Director of Research
IVC Evidensia
 

Neeraj Agrawal

Managing Director
Felix Generics

Neeraj Agrawal

Managing Director
Felix Generics

Neeraj Agrawal

Managing Director
Felix Generics
 

Steve Gibson

Chief Commercial Officer
Strangeworks

Steve has held a range of C-Suite positions in technology companies ranging from financial technology services, to data science consulting. Currently he serves as Chief Commercial Officer at Strangeworks; an advanced compute platform as a service (PaaS) company based in Austin, Texas. Prior to Strangeworks, Steve helped build several startups from the ground up, the most successful being Honest Dollar which was the first startup acquired by Goldman Sachs in their 147 year history.

Steve Gibson

Chief Commercial Officer
Strangeworks

Steve Gibson

Chief Commercial Officer
Strangeworks

Steve has held a range of C-Suite positions in technology companies ranging from financial technology services, to data science consulting. Currently he serves as Chief Commercial Officer at Strangeworks; an advanced compute platform as a service (PaaS) company based in Austin, Texas. Prior to Strangeworks, Steve helped build several startups from the ground up, the most successful being Honest Dollar which was the first startup acquired by Goldman Sachs in their 147 year history. Prior to Honest Dollar, Steve worked for a number of large multinational corporations in the European aerospace sector delivering platforms for military, civil and space applications. Steve holds a Bachelor’s degree in Aerospace Systems Engineering from the University of Coventry in the UK.

 

Danielle J. Healey

Partner
Spencer Fane

Danielle J. Healey

Partner
Spencer Fane

Danielle J. Healey

Partner
Spencer Fane
 

Barbara Fiacco

Partner
Foley Hoag LLP

Barbara Fiacco

Partner
Foley Hoag LLP

Barbara Fiacco

Partner
Foley Hoag LLP